|
|
|
Insider
Information: |
Labrucherie Gil M |
Relationship: |
Chief Financial Officer |
City: |
San Carlos |
State: |
CA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
3 |
|
Direct
Shares |
319,155 |
|
Indirect Shares
|
94,335 |
|
|
Direct
Value |
$392,224 |
|
|
Indirect Value
|
$381,999 |
|
|
Total
Shares |
413,490 |
|
|
Total
Value |
$774,223 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
6
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
0
|
6
|
|
|
|
Gain/Loss Ratio : |
0.0
|
-6.0
|
Percentage
Gain/Loss : |
0.0%
|
-181.1%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Nektar Therapeutics |
NKTR |
SVP, COO & CFO |
2022-05-16 |
312,905 |
2008-11-14 |
0 |
Premium* |
|
Rezolute, Inc |
RZLT |
Director |
2022-05-04 |
0 |
2022-05-04 |
53,572 |
Premium* |
|
Acelyrin, Inc. |
SLRN |
Chief Financial Officer |
2023-10-04 |
6,250 |
2023-10-04 |
40,763 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
104 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 2 of 5
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
|
2018-11-16 |
4 |
S |
$38.25 |
$249,199 |
D/D |
(6,515) |
106,544 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
|
2018-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
28,750 |
135,294 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
|
2019-02-19 |
4 |
S |
$42.39 |
$152,265 |
D/D |
(3,592) |
131,702 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
|
2019-05-16 |
4 |
S |
$31.37 |
$118,171 |
D/D |
(3,767) |
127,935 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
|
2019-06-17 |
4 |
OE |
$7.21 |
$180,250 |
D/D |
25,000 |
152,935 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
|
2019-06-17 |
4 |
AS |
$33.71 |
$842,750 |
D/D |
(25,000) |
127,935 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
|
2019-07-10 |
4 |
OE |
$7.21 |
$180,250 |
D/D |
25,000 |
152,935 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
|
2019-07-10 |
4 |
AS |
$34.57 |
$864,250 |
D/D |
(25,000) |
127,935 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
|
2019-08-14 |
4 |
AS |
$17.79 |
$444,750 |
D/D |
(25,000) |
127,935 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
|
2019-08-14 |
4 |
OE |
$7.21 |
$180,250 |
D/D |
25,000 |
152,935 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
|
2019-08-16 |
4 |
S |
$18.15 |
$91,893 |
D/D |
(5,063) |
122,872 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
|
2019-08-26 |
4 |
OE |
$16.31 |
$489,300 |
D/D |
30,000 |
152,872 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
|
2019-09-16 |
4 |
OE |
$7.21 |
$180,250 |
D/D |
25,000 |
177,872 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
|
2019-09-16 |
4 |
AS |
$20.52 |
$513,000 |
D/D |
(25,000) |
152,872 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP & General Counsel |
|
2008-11-14 |
4 |
S |
$4.37 |
$1,752 |
D/D |
(401) |
1,968 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP & General Counsel |
|
2008-11-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,122 |
2,369 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP & General Counsel |
|
2009-05-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,089 |
3,057 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP & General Counsel |
|
2009-05-12 |
4 |
S |
$5.57 |
$2,200 |
D/D |
(395) |
2,662 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP & General Counsel |
|
2011-03-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,089 |
3,057 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP & General Counsel |
|
2014-11-03 |
4 |
OE |
$11.38 |
$112,662 |
D/D |
9,900 |
13,651 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP & General Counsel |
|
2014-11-03 |
4 |
AS |
$13.78 |
$136,422 |
D/D |
(9,900) |
3,751 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP & General Counsel |
|
2014-11-24 |
4 |
AS |
$15.04 |
$157,920 |
D/D |
(10,500) |
3,751 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP & General Counsel |
|
2014-11-24 |
4 |
OE |
$13.02 |
$136,710 |
D/D |
10,500 |
14,251 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP & General Counsel |
|
2014-11-28 |
4 |
AS |
$17.02 |
$1,531,800 |
D/D |
(90,000) |
4,251 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP & General Counsel |
|
2014-11-28 |
4 |
OE |
$4.65 |
$418,500 |
D/D |
90,000 |
94,251 |
0 |
- |
|
104 Records found
|
|
Page 2 of 5 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|